The characterization of brain alterations associated to the presence of psychotic symptoms has the potential of revealing neural biomarkers of psychosis, which will help the diagnosis and treatment of psychotic disorders. Neuroimaging represents a unique tool for the identification of biomarkers in vivo and in human patients. 22q11.2 deletion syndrome is a neurogenetic disease predisposing to a high risk of schizophrenia and therefore considered a model of the disease. In this symposium the authors will present neuroimaging findings in patients with 22q11DS using different imaging modalities (structural MRI, diffusion tensor imaging, resting-state fMRI). In particular, the presentations will focus on alterations in brain morphology and connectivity associated to more severe psychotic symptoms, which may serve as biomarkers of increased risk of psychosis.